EGFR inhibitors such as erlotinib and gefitinib have become effective options to treat lung cancer; however, it was relatively less successful due to side effects and mutations in EGFR, causing resistance to the treatment which hindered these inhibitors as mainstream agents to treat lung cancer patients. This evidence concerns the gene EGFR and lung carcinoma.